Skip to content
Cimzia(certolizumab pegol)
Cimzia (certolizumab pegol) is an antibody pharmaceutical. Certolizumab pegol was first approved as Cimzia on 2008-04-22. It is used to treat ankylosing spondylitis, crohn disease, psoriatic arthritis, and rheumatoid arthritis in the USA. It has been approved in Europe to treat rheumatoid arthritis. The pharmaceutical is active against tumor necrosis factor.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
musculoskeletal diseasesD009140
digestive system diseasesD004066
skin and connective tissue diseasesD017437
immune system diseasesD007154
Trade Name
FDA
EMA
Cimzia
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Certolizumab pegol
Tradename
Proper name
Company
Number
Date
Products
Cimziacertolizumab pegolUCBN-125160 RX2008-04-22
2 products
Labels
FDA
EMA
Brand Name
Status
Last Update
cimziaBiologic Licensing Application2021-03-24
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
ankylosing spondylitisEFO_0003898D013167M45
crohn diseaseEFO_0000384D003424K50
psoriatic arthritisEFO_0003778D015535L40.5
rheumatoid arthritisEFO_0000685D001172M06.9
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
L04: Immunosuppressants
L04A: Immunosuppressants
L04AB: Tumor necrosis factor alpha (tnf-alpha) inhibitors
L04AB05: Certolizumab pegol
HCPCS
Code
Description
J0717
Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)
Clinical
Clinical Trials
111 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Rheumatoid arthritisD001172EFO_0000685M06.9432914756
Crohn diseaseD003424EFO_0000384K5035163532
Psoriatic arthritisD015535EFO_0003778L40.531116
Ankylosing spondylitisD013167EFO_0003898M4521115
HypertensionD006973EFO_0000537I1011
Anterior uveitisD014606EFO_100081111
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PsoriasisD011565EFO_0000676L40135210
Interstitial cystitisD018856EFO_1000869N30.111
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Ulcerative colitisD003093EFO_0000729K51112
Antiphospholipid syndromeD016736EFO_0002689D68.6111
Pregnancy complicationsD01124811
High-risk pregnancyD01856611
Lung neoplasmsD008175C34.9011
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients22
Adenocarcinoma of lungD00007719211
MelanomaD00854511
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Pregnancy rateD01887322
Inflammatory bowel diseasesD015212EFO_000376711
Cardiovascular diseasesD002318EFO_0000319I9811
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCERTOLIZUMAB PEGOL
INNcertolizumab pegol
Description
Certolizumab pegol, sold under the brand name Cimzia, is a biologic medication for the treatment of Crohn's disease, rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. It is a fragment of a monoclonal antibody specific to tumor necrosis factor alpha (TNF-α) and is manufactured by UCB.
Classification
Antibody
Drug classmonoclonal antibodies; PEGylated compounds, covalent attachment of macrogol (polyethylene glycol) polymer
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Identifiers
PDB
CAS-ID428863-50-7
RxCUI709271
ChEMBL IDCHEMBL1201831
ChEBI ID
PubChem CID
DrugBankDB08904
UNII IDUMD07X179E (ChemIDplus, GSRS)
Target
Agency Approved
TNF
TNF
Organism
Homo sapiens
Gene name
TNF
Gene synonyms
TNFA, TNFSF2
NCBI Gene ID
Protein name
tumor necrosis factor
Protein synonyms
APC1 protein, Cachectin, TNF, macrophage-derived, TNF, monocyte-derived, TNF-a, TNF-alpha, tumor necrosis factor ligand 1F, Tumor necrosis factor ligand superfamily member 2, tumor necrosis factor-alpha, tumor necrotic factor alpha
Uniprot ID
Mouse ortholog
Tnf (21926)
tumor necrosis factor (P06804)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 4,268 documents
View more details
Safety
Black-box Warning
Black-box warning for: Cimzia
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
799 adverse events reported
View more details